Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry ...